A Double-Blinded Study on Rapid and Sustained Pain Relief Topical Cannabidiol for Plantar Fasciitis
Topical Cannabidiol for Plantar Fasciitis: A Double-Blinded Study on Rapid and Sustained Pain Relief
研究概览
详细说明
Plantar fasciitis is one of the most common causes of plantar heel pain, affecting millions of adults annually and accounting for a large proportion of musculoskeletal complaints seen in orthopaedic and sports medicine clinics. The condition is typically caused by repetitive microtrauma and inflammation at the plantar fascia's insertion on the calcaneus, leading to chronic pain, functional impairment, and limitations in daily activities. Despite its prevalence, effective and well-tolerated long-term treatments remain limited. Current management strategies, including stretching, orthotics, corticosteroid injections, and physical therapy, often provide only temporary relief or are associated with adverse effects from repeated use.
Cannabidiol (CBD), a non-psychoactive phytocannabinoid derived from hemp, has gained attention for its potential anti-inflammatory and analgesic properties. Preclinical and clinical studies have demonstrated CBD's ability to modulate inflammatory markers, reduce cytokine activity, and improve pain perception in various musculoskeletal and neuropathic conditions. These mechanisms make it a promising candidate for targeting inflammation-driven pain disorders such as plantar fasciitis. Although CBD has been studied for arthritis, tendon injuries, and generalized pain syndromes, no published trials have yet evaluated its efficacy in plantar fasciitis specifically.
A recent scoping review on topical CBD interventions confirmed this absence of evidence, highlighting a significant gap in the current literature regarding CBD's role in localized foot and heel pain. This lack of research underscores an unmet clinical need to assess whether transdermal delivery of CBD could provide measurable short- and long-term benefits in patients with plantar fasciitis.
This study aims to address that gap by evaluating a 6000 mg transdermal CBD cream (Tolcylen®, Marlinz Pharma) for both immediate and sustained pain reduction in adults with plantar fasciitis. By using a randomized, double-blinded, placebo-controlled design, we intend to determine whether topical CBD can offer a safe, non-invasive, and effective alternative or adjunct to current treatments. The results of this investigation may contribute to the emerging evidence on topical cannabinoids in orthopaedic pain management and inform future clinical practice guidelines.
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习联系方式
- 姓名:Shea Herlihy, MS
- 电话号码:352-273-7361
- 邮箱:herliso@ortho.ufl.edu
研究联系人备份
- 姓名:Antony Merendino, DPM
- 电话号码:352-273-7044
- 邮箱:merena@ortho.ufl.edu
学习地点
-
-
Florida
-
Gainesville、Florida、美国、32611
- University of Florida Department of Orthopaedics
-
接触:
- Shea Herlihy, MS
- 电话号码:352-273-7361
- 邮箱:herliso@ortho.ufl.edu
-
接触:
- Antony Merendino, DPM
- 电话号码:352-273-7044
- 邮箱:merena@ortho.ufl.edu
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
- Patients aged 18-85
- Clinical diagnosis of plantar fasciitis by a qualified provider
- Symptomatic for at least four weeks with plantar heel pain consistent with plantar fascia involvement
- Baseline average pain score that meets eligibility threshold as defined in the protocol (?)
- Willing to apply assigned cream once daily and attend needed visits (?)
Exclusion Criteria:
- Special populations and consent limitations. Pregnancy, breastfeeding, prisoners, inability to provide informed consent, or inability to complete study procedures
- Contraindications to topical products or CBD. History of allergy or sensitivity to cannabinoids, excipients, or topical creams used in the study
- Confounding dermatologic conditions at the application site. Open wounds, active infection, dermatitis, ulceration, or recent burns on the heel or midfoot
- Recent or planned procedures that alter outcomes. Corticosteroid injection, platelet rich plasma, surgery, immobilization, or shockwave therapy within the protocol washout window
- Concurrent therapies that confound pain outcomes. Routine use of systemic opioids, regular use of nonsteroidal anti-inflammatory drugs beyond rescue parameters, new analgesic starts during the study, or use of other topical analgesics on the study area
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:单身的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Participants who receive a transdermal cannabidiol cream
Dosing is three pumps per application which delivers approximately one point five milliliters of cream.
Application is once daily to the most tender plantar fascia region for the entire study month
|
The active product is the study CBD cream supplied by the manufacturer.
Dosing is three pumps per application which delivers approximately one point five milliliters of cream.
Application is once daily to the most tender plantar fascia region for the entire study month.
The first dose will be taught and supervised in clinic using a glove.
The cream will be massaged into the affected area for at least forty-five seconds.
Skin must be clean and dry before application.
No other topical agents may be placed on the study area during the study period.
|
|
安慰剂比较:Participants who receive a matched placebo
Dosing is three pumps per application which delivers approximately one point five milliliters of cream.
Application is once daily to the most tender plantar fascia region for the entire study month
|
The control group will receive a placebo cream identical in appearance, texture, scent, and packaging to the active product but containing no cannabidiol.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
• Immediate pain relief, measured by change in numeric rating scale (0-10) from baseline to ten minutes after supervised application.
大体时间:Daily for one month
|
Daily for one month
|
|
|
• One-month changes in average daily pain score compared to baseline.
大体时间:Daily for one month
|
Daily for one month
|
|
|
• Global patient satisfaction
大体时间:Daily for one month.
|
measured using a five-point Likert scale assessing overall perceived improvement.
|
Daily for one month.
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Duration of immediate pain relief following initial application
大体时间:Daily for one month
|
Daily for one month
|
|
|
Adherence to protocol measured by patient logs and pump counts
大体时间:Daily for one month
|
Daily for one month
|
|
|
Incidence of adverse effects
大体时间:Daily for one month
|
Occurrence of negative side effects
|
Daily for one month
|
|
Rescue analgesic use
大体时间:Daily for one month
|
Daily for one month
|
|
|
Time to perceived improvement in symptoms
大体时间:Daily for one month
|
Daily for one month
|
|
|
6. PROMIS Pain Interference questionnaire
大体时间:At enrollment and at end of once month
|
At enrollment and at end of once month
|
|
|
7. Foot Function Index questionnaires
大体时间:At enrollment and at one month
|
At enrollment and at one month
|
|
|
8. Return to normal activity - the number of days required for participants to resume full standing or walking tolerance without pain
大体时间:Once during one month
|
Once during one month
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.